09939 KINTOR PHARMA-B
- 1.240
- 0.0000.00%
KINTOR PHARMA-B News
Changes in Hong Kong stocks | The collective decline in pharmaceutical stocks will improve the quality and expansion of pharmaceutical procurement, which is expected to form a national alliance for procurement
Pharmaceutical stocks fell collectively today. As of press release, Luye Pharmaceuticals (02186) fell 7.72% to HK$2.75; Kaituo Pharmaceutical-B (09939) fell 7.35% to HK$1.26; Zhongsheng Pharmaceuticals (01177) fell 5.75% to HK$2.95; and Cinda Biotech (01801) fell 4.61% to HK$38.3.
Improve quality and expand! The National Health Insurance Administration issued a new collection document “There is a lot of information” to set the tone for new trends in collection and procurement
① Yesterday evening, the National Health Insurance Administration issued the “Notice on Strengthening Regional Collaboration to Improve Quality and Expand Centralized Pharmaceutical Procurement in 2024", which provides further instructions on “improving quality and expansion” of collection; ② Many interprovincial alliance procurement will soon be upgraded to national joint procurement, which has attracted strong attention from the industry. In particular, the provinces covered by the Sanming Alliance and Henan Alternative Medicine Alliance will be further expanded, and proprietary Chinese medicine and Chinese medicine tablet companies need to prepare early.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
開拓藥業-B：年報 2023
Kaituo Pharmaceutical-B (09939.HK): Restitution of land use rights located in Pinghu City, Zhejiang Province, China
Kaituo Pharmaceutical-B (09939.HK) announced that on April 25, 2024, the seller Kaituo Pharmaceutical (Zhejiang) Co., Ltd. (a wholly-owned subsidiary between the companies) signed an agreement with the buyer Zhejiang Dushan Port Economic Development Zone Management Committee. According to the agreement, the seller agreed to return the land use rights located in Pinghu City, Zhejiang Province, China, at a cost of approximately RMB 26.07 million.
Changes in Hong Kong stocks 丨 Kaituo Pharmaceutical once surged 27%, and the drug to treat hair loss reached the main end point of phase II clinical trials
Gelonghui, April 22 | Kaituo Pharmaceutical-B (9939.HK) surged 27.59% to HK$1.11 at the beginning of the session. According to the news, the company announced that it has independently developed a novel proteolytic chimeric compound GT20029 targeting androgen receptors. The Chinese phase II clinical trial for topical treatment of male androgenic alopecia has reached the main research end, and will actively deploy subsequent clinical strategies for GT20029, such as carrying out phase III clinical trials in China for male hair loss and phase II clinical trials in the US. Additionally, the company is preparing to conduct a phase II clinical trial of GT20029 for acne treatment
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment
Kintor Pharmaceutical (HKG:9939) said it completed the Phase II clinical trials for its Androgenic Alopecia treatment GT20029 in China, according to a Sunday filing on the Hong Kong bourse. The pharma
Changes in Hong Kong stocks | Pioneer Pharmaceutical-B (09939) opens nearly 15% GT20029 to treat male hair loss, China's phase II clinical trial reached the main end
Kaituo Pharmaceutical-B (09939) rose by nearly 15%. As of press release, it rose 14.94% to HK$1, with a turnover of HK$81,000.
Selected announcements | China Tower's Q1 net profit increased 11.1%; China Unicom's Q1 net profit increased 8.9%
The number of passengers carried by Cathay Pacific increased by 40% in March; China Telecom increased the net number of users by 1.91 million in March.
Express News | Pioneering the pharmaceutical industry: GT20029 Chinese phase II clinical trial to treat male hair loss reached the main end
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Develop the pharmaceutical industry's 2023 performance: explore Pico's multi-channel commercialization path and dig deeper into multi-pipeline R&D and commercial value
SUZHOU, March 29, 2024/PRNewswire/ -- On March 29, 2024, Beijing time, Kaituo Pharmaceutical (stock code: 9939.HK), a biopharmaceutical company focused on the development and industrialization of potential pioneers and best-in-class innovative drugs, announced recent business highlights and annual results for the year ending December 31, 2023. 2023 Annual Results Overview Business Overview Pico Dual Core Products Global Clinical Research and Development Continues to Advance Multiple Pipelines Reveal the Value of R&D and Commercial Cooperation Multiple Research Results Selected for Important Academic Conferences and Financial Overview Funding in Core Journals
Kaituo Pharmaceutical-B (09939) announced its 2023 annual results, with a net loss of 1.06 billion yuan, an increase of 11.2% over the previous year
Kaituo Pharmaceutical-B (09939) announced the results for the year ended December 31, 2023, and the Group has not approved the entry...
Analysis
Price Target
No Data
